Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Cell and Gene Therapy Insights 2026; 12(9), 889–910 10.18609/cgti.2026.112 Recombinant adeno-associated virus (rAAV) has emerged as a leading platform for gene therapy, leveraging both naturally occurring and engineered capsids to deliver therapeutic transgenes. As clinical and research demand for rAAV has grown, vector quality and manufacturing consistency have become critical considerations.
Cell & Gene Therapy Insights 2023; 9(4), 265–273 DOI: 10.18609/cgti.2023.085 Adeno-associated viruses (AAVs) are non-pathogenic parvoviruses that have been successfully adapted as gene therapy vectors. Originally discovered as contaminants of adenovirus preparations, and despite decades of research using tissue culture models, the natural biology of AAVs remains largely unknown.
Phylogenetic analysis reveals the evolutionary history of subfamily Parvovirinae Via Parvovirus-GLUE, we implemented a reproducible and extensible process (S6 Fig) for reconstructing evolutionary relationships across the entire Parvoviridae, at a range of taxonomic levels. Phylogenies were reconstructed using maximum likelihood (ML), firstly among viruses only (S7 Fig), and secondly among both viruses and EPVs (Figs 4–8 and S8-S13).
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
